Logotype for Acutaas Chemicals Limited

Acutaas Chemicals (ACUTAAS) Q2 25/26 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Acutaas Chemicals Limited

Q2 25/26 earnings summary

8 Jul, 2026

Executive summary

  • Revenue for Q2 FY26 grew 24.1% year-on-year to INR 306.2 crore (₹3,062 million), driven by advanced pharmaceutical intermediates and stable specialty chemicals performance.

  • EBITDA for Q2 FY26 increased 94.8% year-on-year to ₹953 million, with PAT up 91.3% to ₹719 million.

  • The company is building long-term sustainable business across diversified verticals: pharmaceutical, battery chemicals, semiconductors, cosmetics, and specialty chemicals.

  • Battery chemical business has secured multiple customers globally; production to commence in Q4 FY26 post CapEx completion.

  • Unaudited standalone and consolidated financial results for Q2 and H1 FY2026 were approved on October 17, 2025, with a limited review by statutory auditors confirming no material misstatements.

Financial highlights

  • Q2 FY26 revenue: INR 306.2 crore (₹3,062 million), up 24.1% YOY; H1 FY26 revenue: INR 513.4 crore (₹5,134 million), up 21.3% YOY.

  • Q2 FY26 gross profit: INR 170.7 crore (₹1,707 million), up 59.3% YOY; gross margin expanded to 55.8%-56%.

  • Q2 FY26 EBITDA: INR 95.3 crore (₹953 million), nearly doubled YOY; EBITDA margin at 31.1%.

  • Q2 FY26 PAT: INR 71.9 crore (₹719 million), up 91.3% YOY; PAT margin at 23.5%.

  • Net cash and cash equivalents at INR 240.6 crore as of 30 September 2025.

  • Cash from operations in H1 FY26: INR 136.5 crore.

  • Basic and diluted EPS (standalone) for Q2 FY2026 were ₹8.90; for H1 FY2026, ₹14.36.

Outlook and guidance

  • Revenue growth guidance for FY26 maintained at around 25%.

  • EBITDA margin guidance revised to 28%-30% for FY26, expected to be sustainable in coming years due to improved product mix and operational efficiency.

  • Battery chemicals and semiconductor verticals expected to be key growth drivers; electrolyte additive CapEx to be completed by Q4 FY26, with full contribution in FY27.

  • The company continues to focus on custom synthesis and manufacturing of specialty chemicals for pharmaceutical APIs and related sectors.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more